49. Systemic lupus erythematosus Clinical trials / Disease details
Clinical trials : 946 / Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03878303 (ClinicalTrials.gov) | November 28, 2018 | 5/3/2019 | Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE) | A Phase 1b Double-Blind, Randomized, Placebo-Controlled Study of the Safety, Pharmacokinetics and Pharmacodynamics of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | Drug: AC0058TA;Drug: Placebo AC0058TA | ACEA Therapeutics, Inc. | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | Recruiting | 18 Years | 75 Years | All | 32 | Phase 1 | United States |